तुलना करने के लिए मीट्रिक्स | IVAA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIVAAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.9x | −2.4x | −0.4x | |
PEG अनुपात | −0.04 | −0.01 | 0.00 | |
क़ीमत/बुक | 12.2x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 293.4x | 5.5x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 228.5% | 308.6% | 56.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.1% | 7.9% | अनलॉक करें |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.